Bevacizumab and t-PA in Vitrectomy for Diabetic Retinopathy
Author Information
Author(s): Aras Cengiz, Senturk Fevzi, Erdur Sevil Karaman, Kocabora Mehmet Selim, Dogramaci Mahmut, Burke Cahit, Aras Efe
Primary Institution: Istanbul Medipol University
Hypothesis
Does the co-application of bevacizumab and tissue plasminogen activator improve surgical outcomes in vitrectomy for proliferative diabetic retinopathy?
Conclusion
The co-application of bevacizumab and tissue plasminogen activator shortens surgery time and reduces intraoperative retinal breaks in diabetic retinopathy surgery.
Supporting Evidence
- The mean surgery time was significantly shorter in the group receiving both medications.
- The number of iatrogenic retinal breaks was lower in the group receiving both medications.
- Visual acuity improved significantly in both groups after surgery.
Takeaway
Doctors used two medicines before eye surgery to help patients with diabetes. This made the surgery faster and safer.
Methodology
A prospective, randomized, single-masked, comparative analysis was performed with patients receiving either bevacizumab and t-PA or bevacizumab alone before vitrectomy.
Potential Biases
Possible biased conclusions due to the variability in patient conditions and the single-surgeon approach.
Limitations
The study had a small sample size and potential bias due to the heterogeneity of tractional membranes.
Participant Demographics
40 patients with proliferative diabetic retinopathy, mean age 51.57 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website